GENEDX HOLDINGS CORP
GeneDx Holdings Corp (WGS) is a clinical genetic testing company that offers diagnostic genomic services for rare disease, hereditary conditions and other specialised indications. With a market capitalisation of about $3.50 billion, the business derives revenue from laboratory testing, interpretation services and partnerships with clinicians and biopharma. Investors should note the company operates in a fast-evolving field: wider adoption of genomic testing and advances in sequencing can support growth, while reimbursement policies, competition and regulatory scrutiny can affect margins and volume. Key considerations include the company’s ability to scale testing, protect patient data, manage costs of technology and secure favourable payer coverage. As with most healthcare and diagnostics stocks, shares can be volatile and long-term outcomes depend on clinical utility, commercial execution and the regulatory environment. This summary is educational and not investment advice; investors should assess suitability for their own situation and consider consulting a financial adviser.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GeneDx stock with a target price of $167, indicating significant growth potential.
Financial Health
Genedx Holdings Corp is showing strong revenue and cash flow, with healthy profitability margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring WGS
The Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growing testing demand
Increasing clinical acceptance of genomic testing could support volume growth, though reimbursement and payer coverage remain important constraints.
Technology and scale
Sequencing and data analytics can be differentiators if the company scales efficiently, but R&D and equipment costs may pressure margins.
Regulation and access
International expansion and partnerships offer opportunity, yet regulatory variation and data‑privacy rules can complicate market access.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.